Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/33853
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2023-09-14T13:00:33Z-
dc.date.available2023-09-14T13:00:33Z-
dc.date.issued2014-01-18-
dc.identifier.citationCander, S. vd. (2014). "Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-Week, crossover, treat to target trial in a single center". Primary Care Diabetes, 8(3), 256-264.en_US
dc.identifier.issn1751-9918-
dc.identifier.issn1878-0210-
dc.identifier.urihttps://doi.org/10.1016/j.pcd.2014.01.010-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1751991814000114-
dc.identifier.urihttp://hdl.handle.net/11452/33853-
dc.description.abstractAim: To compare once- versus twice-daily insulin detemir added on OADS therapy in insulin-naive type 2 diabetes patients in terms of efficacy and safety. Methods: An open-label study performed at a single center, comprised a randomized, crossover 24 week with insulin-naive type 2 diabetes patients. Insulin detemir was initiated with mean 0.12 U/kg in all patients (Group I once-daily, Group II twice-daily) and titrated for 24 week. Results: A total of 50 patients completed the study (Group I n:25, Group II n:25). With use of once- and twice-daily insulin, HbA1c values were decreased by 1.8% (+/- 2.0) and 1.5% (+/- 1.4) within the first 12 weeks (p<0.01), whereas increased by 0.21% (+/- 0.7) and 0.14% (+/- 0.8) in the second 12 weeks (p>0.05). The increases in the insulin doses were found as 0.22 U/kg and 0.35 U/kg with once- and twice-daily insulin use, respectively (p:0.04). Although minor hypoglycemic events were similar in both groups in the first 12 weeks, 2-fold increase was found in the patients shifting from once- to twice-daily dose. Within the first and second periods, the body weight of the patients was observed an increase of 0.4 and 1.6 kg with once-daily dose, whereas a decrease of 0.1 and 2.1 kg in the twice-daily dose, in the same period. Conclusion: Once-daily use of insulin detemir up to 0.4 U/kg was found to have similar efficacy and safety as twice-daily use. Twice dose use of insulin did not provide a prominent glycemic control advantage on 1.5-fold higher use of insulin.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDetemiren_US
dc.subjectType 2 diabetesen_US
dc.subjectHbA1cen_US
dc.subjectOnce dailyen_US
dc.subjectHypoglycemiaen_US
dc.subjectInsulin doseen_US
dc.subjectImproves glycemic controlen_US
dc.subjectVariabilityen_US
dc.subjectNph insulinen_US
dc.subjectAnalogen_US
dc.subjectWeight-gainen_US
dc.subjectTherapyen_US
dc.subjectDouble-blinden_US
dc.subjectHypoglycemiaen_US
dc.subjectGlargineen_US
dc.subjectPredictive(tm)en_US
dc.subjectEndocrinology & metabolismen_US
dc.subjectGeneral & internal medicineen_US
dc.subject.meshAdministration, oralen_US
dc.subject.meshBiological markersen_US
dc.subject.meshBlood glucoseen_US
dc.subject.meshCross-over studiesen_US
dc.subject.meshDiabetes mellitus, type 2en_US
dc.subject.meshDrug administration scheduleen_US
dc.subject.meshDrug therapy, combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHemoglobin a, glycosylateden_US
dc.subject.meshHumansen_US
dc.subject.meshHypoglycemiaen_US
dc.subject.meshHypoglycemic agentsen_US
dc.subject.meshInjectionsen_US
dc.subject.meshInsulin, long-actingen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshTime factorsen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshTurkeyen_US
dc.subject.meshWeight gainen_US
dc.titleComparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-Week, crossover, treat to target trial in a single centeren_US
dc.typeArticleen_US
dc.identifier.wos000342255700011tr_TR
dc.identifier.scopus2-s2.0-84908356193tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0001-5082-9894tr_TR
dc.identifier.startpage256tr_TR
dc.identifier.endpage264tr_TR
dc.identifier.volume8tr_TR
dc.identifier.issue3tr_TR
dc.relation.journalPrimary Care Diabetesen_US
dc.contributor.buuauthorCander, Soner-
dc.contributor.buuauthorDizdar, Oğuzhan Sıtkı-
dc.contributor.buuauthorÖz Gül, Özen-
dc.contributor.buuauthorGüçlü, Metin-
dc.contributor.buuauthorÜnal, Oǧuz Kaan-
dc.contributor.buuauthorTuncel, Ercan-
dc.contributor.buuauthorErtürk, Erdinç-
dc.contributor.buuauthorİmamoğlu, Şazi-
dc.contributor.buuauthorErsoy, Canan Özyardımcı-
dc.contributor.researcheridAAJ-6536-2021tr_TR
dc.contributor.researcheridAAH-8861-2021tr_TR
dc.contributor.researcheridAAI-1005-2021tr_TR
dc.contributor.researcheridABI-4847-2020tr_TR
dc.identifier.pubmed24522170tr_TR
dc.subject.wosEndocrinology & metabolismen_US
dc.subject.wosPrimary health careen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.contributor.scopusid25027068600tr_TR
dc.contributor.scopusid55202193000tr_TR
dc.contributor.scopusid26040787100tr_TR
dc.contributor.scopusid15073842600tr_TR
dc.contributor.scopusid55042241400tr_TR
dc.contributor.scopusid7006929833tr_TR
dc.contributor.scopusid7005488796tr_TR
dc.contributor.scopusid6602297533tr_TR
dc.contributor.scopusid6701485882tr_TR
dc.subject.scopusInsulin Glargine; Insulin Replacement Therapy; Non Insulin Dependent Diabetes Mellitusen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeCrossover procedureen_US
dc.subject.emtreeDiabetic patienten_US
dc.subject.emtreeDosage schedule comparisonen_US
dc.subject.emtreeDrug dose increaseen_US
dc.subject.emtreeDrug dose titrationen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug safetyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGlycemic controlen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInsulin hypoglycemiaen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNon insulin dependent diabetes mellitusen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.emtreeTreatment durationen_US
dc.subject.emtreeWeight gainen_US
dc.subject.emtreeBlooden_US
dc.subject.emtreeChemically induceden_US
dc.subject.emtreeComparative studyen_US
dc.subject.emtreeDiabetes mellitus, type 2en_US
dc.subject.emtreeDrug administrationen_US
dc.subject.emtreeDrug combinationen_US
dc.subject.emtreeDrug effectsen_US
dc.subject.emtreeGlucose blood levelen_US
dc.subject.emtreeHypoglycemiaen_US
dc.subject.emtreeInjectionen_US
dc.subject.emtreeMetabolismen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeOral drug administrationen_US
dc.subject.emtreeTimeen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeTurkeyen_US
dc.subject.emtreeHemoglobin a1cen_US
dc.subject.emtreeInsulin detemiren_US
dc.subject.emtreeOral antidiabetic agenten_US
dc.subject.emtreeAntidiabetic agenten_US
dc.subject.emtreeBiological markeren_US
dc.subject.emtreeGlucose blood levelen_US
dc.subject.emtreeGlycosylated hemoglobinen_US
dc.subject.emtreeHemoglobin a1c protein, humanen_US
dc.subject.emtreeInsulin detemiren_US
dc.subject.emtreeLong acting insulinen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.